GliaCure raises $5.8 million for Alzheimer’s drug that treats the glial cells
Boston-based GliaCure is taking a slightly different approach to treating Alzheimer’s disease – instead of targeting the neurons, its drug compound focuses on glial cells – a cell type that’s generally overlooked in drug development. It has raised a $5.8 million oversubscribed Series B round, exceeding its initial goal of $5 million. The funding comes […]